Haitian-born billionaire Herriot Tabuteau's Axsome begins Phase 3 ADHD trial in children
Axsome Therapeutics, led by Haitian-born billionaire Herriot Tabuteau, has dosed the first child in a Phase 3 trial of solriamfetol for ADHD.
Biotech
Skip to content
Axsome Therapeutics, led by Haitian-born billionaire Herriot Tabuteau, has dosed the first child in a Phase 3 trial of solriamfetol for ADHD.